Pyridine

Pyridine

SCHEMBL4898097

N#Cc1c(Cl)nc(NC2CC2)nc1Cl.c1ccncc1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CTSK P43235 3/20 0.38
CTSS P25774 2/20 0.38
CTSV O60911 1/20 0.38
PLAT P00750 1/20 0.38
CTSL P07711 1/20 0.38
CTSH P09668 1/20 0.38
CASP14 P31944 1/20 0.38
CASP6 P55212 1/20 0.38
CTSZ Q9UBR2 1/20 0.38
PDE4A P27815 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907067 0.87 PDE4A (0.44) ACHECTSKCTSSCTSVPLAT
SCHEMBL4908292 0.79 KMT2A (0.56) ACHEKMT2AMEN1PDE4AKDM4E
SCHEMBL4416389 0.78 ACHE (0.43) ACHECTSKCTSSCTSVPLAT
SCHEMBL4906591 0.74 KMT2A (0.38) ACHEKMT2ACTSKCTSSCTSV
SCHEMBL4907135 0.74 SQOR (0.42) ACHEKMT2AKDM4ESMN1; SMN2MAPK1
SCHEMBL4907005 0.74 ACHE (0.41) ACHEKMT2AMEN1CTSKCTSS
SCHEMBL9640912 0.73 KMT2A (0.45) KMT2AMEN1CTSKCTSSCTSV
SCHEMBL4899212 0.73 KDM1A (0.47) ACHEKMT2AMEN1CTSKCTSS
SCHEMBL4906676 0.73 ACHE (0.43) ACHECTSKCTSSCTSVPLAT
SCHEMBL4904144 0.72 CYP11B1 (0.39) ACHEKMT2AMEN1CTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF ACHE 939/4885KMT2A 3422/4885MEN1 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.